- Total Revenue was $657.7 million, a decrease of 10 percent. On a constant currency basis, Total Revenue declined 9 percent due to a reduction of approximately $60 million in channel inventory driven by factors resulting from the COVID-19 pandemic.
- Gross margin was 49.4 percent of revenue (reported), or 50.1 percent of revenue (adjusted).
- Earnings per share (EPS) was $(0.12) (reported), or $0.13 (adjusted).
- Bayer Animal Health acquisition remains on track for mid-year close; Antitrust approval process progressing; new members of expanded executive leadership team announced.
- Long-term industry fundamentals remain intact; 2020 guidance withdrawn due to uncertainty of the duration and magnitude of impacts from the COVID-19 pandemic.
About Elanco
At Elanco, we are united by a genuine love and care for animals. Our purpose - making life better for animals, makes life better - fuels us to break boundaries and inspires us to push further, transforming animal care for healthier animals and a healthier, more sustainable world.
Elanco's Healthy Purpose, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. © 2025 Elanco or its affiliates.
What's Happening
About Elanco
At Elanco, we are united by a genuine love and care for animals. Our purpose - making life better for animals, makes life better - fuels us to break boundaries and inspires us to push further, transforming animal care for healthier animals and a healthier, more sustainable world.
Elanco's Healthy Purpose, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. © 2025 Elanco or its affiliates.